Loading...
•
Mar 31, 2020
AptarGroup Q1 2020 Earnings Report
AptarGroup's Q1 2020 results were reported.
Key Takeaways
AptarGroup's Q1 2020 results showed a decrease in reported sales by 3% to $722 million, with core sales, excluding currency and acquisition effects, decreasing by 2%. EPS was $0.84, a decrease of 13% compared to the prior year. The Pharma segment saw core sales growth of 7%, offsetting declines in other segments. The company is deemed an essential supplier and is monitoring the COVID-19 pandemic's impact.
Reported sales decreased 3% due to currency exchange rates, lower resin costs, and COVID-19 impacts.
Core sales, excluding currency and acquisition effects, decreased 2%.
Pharma segment core sales grew 7%, offsetting declines in other segments.
Adjusted earnings per share totaled $0.93, an 11% decrease year-over-year.
Revenue by Segment
Forward Guidance
Aptar expects the coming quarter to mark the worst of the expected COVID-19 impacts on our business and we anticipate a gradual recovery in the second half of the year.
Positive Outlook
- Broad portfolio of dispensing, drug delivery and active packaging solutions
- Growing services platforms
- New partnerships
- Balance sheet remains in excellent condition
- Continue to diligently manage costs and capacities
Challenges Ahead
- Duration and severity of the COVID-19 pandemic
- Pace and scope of reopening in regions that are currently under government confinement orders
- Speed at which beauty and other retail stores open
- Willingness of consumers to participate in those shopping channels
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...